Previous 10 | Next 10 |
Ocugen, Inc. (OCGN) Q4 2022 Earnings Conference Call February 27, 2023 08:30 ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer &...
MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it has ...
Ocugen ( NASDAQ: OCGN ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $2.17M For further details see: Ocugen Q4 2022 Earnings Preview
MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’...
Biotech companies are ripe with innovation. And sometimes that can lead to tremendous share gains. The two stocks I'll talk about here -- Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) -- both have soared in recent years on optimism about potentially game-changing products. ...
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. In fact, the shares climbed about 700% in a matter of days. That's when Ocugen gained the right to sell Bharat Biotech's Covaxin in the U.S. It later added...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips For medium to long-term investors, it’s essential to screen fundamentally strong businesses when looking to add exposure to a given sector or type of stock. However, from a trading perspective, an under-performing stock ...
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer,...
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Off...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...